ArticleRevista medica del Instituto Mexicano del Seguro Social2026
[Sleep disorders associated with montelukast in children with respiratory allergy].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma and allergic rhinitis are the most common respiratory allergic disorders in the Mexican population. Montelukast is a leukotriene receptor antagonist that has been widely used in these conditions. An association has been documented with the onset and modification of multiple sleep disorders, as well as other neuropsychiatric alterations in pediatric population. Objective: To analyze the association between montelukast and sleep disorders in children with respiratory allergies. Material and methods: A prospective and analytical cohort study was conducted. Patients aged 5 to 17 years diagnosed with asthma and allergic rhinitis were recruited from a third-level hospital. They were divided into 2 groups: a montelukast user group and a control group. Patients who withdrew their consent or did not complete the questionnaires were excluded. Results: 120 children were analyzed, 60 children using montelukast and 60 not using it. The median age was 9 and 10 years, respectively. Five (4.17%) of the children had asthma as their primary diagnosis, 60 (50%) had allergic rhinitis, and 55 (45.83%) had both asthma and allergic rhinitis. Among the children taking montelukast, 46 (73.02%) had sleep disorders, compared to 17 (14.17%) of those not taking montelukast. The association showed an odds ratio (OR) of 8.31, p < 0.0001. Conclusion: Montelukast use was associated with the presence of sleep disorders in the studied population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.